Chagas disease is one of the most imperative health problems in Latin America. It is caused by the protozoan parasite Trypanosoma cruzi ([@B43], [@B53]). In Mexico, several strains have been isolated. Interestingly, each strain presents with different tissue tropism and severity of the disease ([@B30], [@B7], [@B10]).

Radical nitric oxide (NO) is a small molecule that has multiple biologic activities against parasite infections, such as schistosomiasis, leishmaniasis, toxoplasmosis and trypanosomiasis ([@B19]). The dual role of NO during Chagas disease is currently being deduced. Some researchers have shown that NO levels increase during the acute phase of infection, inhibiting the progression of the disease by destroying the T. cruzi. Interestingly, the NO levels during the chronic phase have been shown to have adverse effects ([@B40], [@B43]). We have demonstrated that subjects infected with T. cruzi during chronic phase of Chagas disease presented with three times higher NO levels in their serum ([@B39], [@B40]). In addition, a positive correlation was found between NO levels and disease severity during the chronic phase ([@B40]), which was not seen during the acute phase of infection. The antimicrobial activity of cytokine-activated macrophages was decreased when they were treated with inducible NO synthase inhibitors, L-imino-ethyl-L-ornithine and N-monomethyl-L-arginine (L-NAME), which allowed parasite proliferation in vitro ([@B51], [@B9]). This data supports the notion that NO levels will limit local inflammation caused by the parasite during the acute phase. However, during the chronic phase of Chagas disease, there is an increase in free radicals that contributes to enhanced oxidative stress and organ damage in patients.

Metallothioneins (MTs), a low-molecular weight protein ([@B50]), protect the cells from a variety of reactive oxidants species, such as hydrogen peroxide and hydroxyl radical, by acting as an antioxidant and a radical scavenger ([@B52], [@B41], [@B50]). MTs are expressed in various organs/tissues and their expression levels can be augmented by inflammatory stimuli, making them an anti-inflammatory mediator ([@B16]). There are four MTs genes (I-IV) ([@B47]). MT-I and MT-II are expressed in various tissues, most notably the liver and kidney. MT-III is mainly found in the brain, whereas MT-IV is expressed primarily in stratified squamous epithelia cells ([@B47]). Evaluation of MTs' protective role showed an increased expression against different aetiologies of oxidative stress, especially in liver tissue ([@B46], [@B20], [@B26]). MT-/- knockout mice also support the role of these proteins as essential antioxidants during oxidative stress ([@B33]). Moreover, by using a restraint stress-induced rat model, the increased stress induced liver MT-I antioxidant activity by increasing MT-I levels in vivo, as determined by elevated liver MT-I mRNA and protein levels ([@B15]). The role of MTs against reactive oxygen species and reactive nitrogen species, having a superior efficiency than superoxide dismutase (SOD) and glutathione (GSH), has been widely documented ([@B48], [@B16], [@B3]). However, the role of liver MT-I in the chronic phase of Chagas disease has not been evaluated.

During the chronic phase of Chagas disease, the production of pro-inflammatory cytokines led to a chronic inflammation, a reduction in antioxidant enzymes SOD and GSH and oxidative stress characterised by high levels of NO in the serum of patients ([@B40]). One of MT's functions is to protect against oxidising agents. Since MTs are antioxidants and their expression has been related to infection and inflammation, it seems suitable to consider the possibility that there is a relationship between NO and MT regulation. The present study is aimed to evaluate the expression of MT-I and its relationship with NO blood serum levels and the effect of L-NAME treatment in a murine model of chronic Chagas using the T. cruzi RyCH1 isolated from Puebla, Mexico.

MATERIALS AND METHODS
=====================

*Strain* - The strain was isolated during epidemiological studies in Puebla. Parasites were genetically characterised as HUM/ME/1997/MEX/RyCH1 or as T. cruzi RyCH1 ([@B44]). Isolates were routinely maintained by intraperitoneal (i.p.) passages in 10-week-old BALB/c mice at four-week intervals.

*Mice, infection and treatments* - BALB/c female mice (8-10 weeks of age and 25 ± 5 g) were allocated at room temperature (21-23ºC). They received water and a commercial diet ad libitum (Alimento Balanceado de la Cienega, SA CV). Mice were obtained and maintained in animal facilities from East Biomedical Research Centre/Mexican Institute of Social Security (Puebla, MX) in compliance with the guidelines Official Mexican Norm NOM-062-ZOO-1999: Technical Specifications for the Production, Care and Use of Laboratory Animals ([@B6]), as well as the International Guiding Principles for Biomedical Research involving animals (CIOMS/ICLAS 2012). The mice were randomly divided into four groups: infected non-treated (Inf) (n = 36), infected L-NAME treated (Inf L-NAME) (n = 36), non-infected L-NAME treated (Non-Inf L-NAME) (n = 36) and non-infected vehicle-treated (Non-Inf Veh) (n = 36). Inf and Inf L-NAME were inoculated i.p. with 1 x 104 trypomastigotes of T. cruzi RyCH1 in 50 μL of 4% sterile sodium citrate on days 0, 30 and 60. Inf L-NAME and Non-Inf L-NAME were treated with 25 mg/Kg of L-NAME (N-nitro-L-arginine methyl ester hydrochloride, Cat: N575, St. Louis, MO) administered by i.p. injections once a week from days 0 through 195. Non-Inf Veh were not infected with T. cruzi RyCH1, yet received i.p. injection of diluents (100 μL sodium citrate 4%). Blood parasitaemia was determined by cutting 1 mm off of the tail tip, followed by counting the number of parasites per mL of blood using a haemocytometer ([@B14]). Additionally, trypomastigotes forms where classify as thin form (small and immature) or thick form (large and mature) according to the specifications of the previously establish ratio method (width/length: w/l) ([@B28]). The mice were euthanised by cervical dislocation (4 mice from each group) after the last bleeding. Tissue samples were collected for an immediate histopathology analysis and liver tissue was isolated and stored at -70ºC until further use.

*Histopathological analyses* - Samples from the heart, skeletal muscle and the large intestine were fixed in 10% formaldehyde, dehydrated in absolute alcohol and then embedded in paraffin. For each organ, serial sections of 5 μm were cut in a microtome. Tissue samples were stained with haematoxylin and eosin (H&E) and then examined by light microscopy using a Zeiss microscope (Carl Zeiss AG, Oberkochen, Germany). Photographs were taken at the indicated magnification with an Olym- pus X-785 digital camera coupled to the microscope. For T. cruzi nests analysis, mice were sacrificed at two and three weeks post-infection (p.i.) and their organs were analysed using H&E staining (heart, diaphragm, oesophagus, colon and skeletal muscle), followed by quantification of amastigote nests and inflammatory infiltrates (more than 10 mononuclear cells) in 100 fields at 100X magnification.

*Measuring the serum levels of NO* - The NO levels were evaluated by measuring the nitrite (NO2-) level in serum samples using the Griess reaction ([@B11], [@B35]). Nitrate was reduced to NO2- using spongy cadmium (5-20-mesh, Sigma). Sodium nitrite (NaNO2) was used to make a standard curve. Sodium nitrate (NaNO3) was used as a standard and to determine reaction efficiency. The overall reaction can be described as following: NO3- + H2O + Cd → NO2- + Cd2+ + 2 OH-. The absorbency was measured at 540 nm in a microplate ELISA reader (Multiskan MS, Labsystems OY, Helsinki, Finland).

*Quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR)* - Liver samples were homogenised with a Polytron Willems (PT10/35) homogeniser (Brinkmann Instruments, Westbury, NY, USA) in 1 mL of TRIzol® (Invitrogen, Grand Island, NY, USA) to 100 mg of liver tissue. The RNA was extracted according to manufacturer's protocol. The cDNA was synthesised using 4 μg of total RNA from liver tissue with 10 U of MMLV reverse transcriptase (Gibco BRL), 2 μL of 10 X buffer without Mg2+, 10 mM dNTPs stock solution \[2.5 mM each of dA, dG, dC and dT (Strategene)\], 50 mM MgCl2 (Gibco BRL), 10 mM oligo-d(T) (Gibco BRL), 5 U ribonuclease inhibitor (Gibco BRL) and 10 mM DTT (Gibco BRL) in 20 μL final volume, followed by incubation for 1 h at 37ºC. Primers were synthesised according to an alignment of the amino acid and nucleotide sequences reported for wild type MT-I mice ([@B29]), sequences MT-I (Fwd):TCCCGAGCATTACTAAA and MT-I (Rev): ACCCCAGTTTCTTATTG. PCR reactions were synthesised using 6 μL of cDNA reaction (6 μg), 2.5 U Taq DNA polymerase (Gibco BRL), 8 μL of 10 X buffer without Mg2+ (Gibco BRL), 10 mM dNTPs stock solution \[2.5 mM each of dA, dG, dC and dT (Strategene)\], 50 mM MgCl2 (Gibco BRL), 20 pmol of each MT-I primers, 0.8 pmol of each G3PDH primers \[G3PDH (Fwd): TGAAGGTCGGTGTGAACGGATTTGGC and G3PDH (Rev): CATGTAGGCCATGAGGTCCACCAC\] in 80 μL final volume. MT-I and G3PDH were amplified simultaneously in PTC-100 Thermal Cycler (MJ Research, Alameda, CA, USA) for 35 cycles (94ºC for 1 min, 54ºC for 1 min and 72ºC for 1 min). PCR products were separated with a 1.5% agarose gel and visualised with 1% ethidium bromide. MT-I copy numbers were divided by G3PDH (housekeeping gene) to standardise the data set.

Statistical analysis - Data is expressed as the mean (average) ± standard error. A two-way ANOVA was performed to determine significant differences between the groups. When this analysis indicated a significance of more than 5%, a post hoc Student-Newman-Keuls analysis was used to determine which groups significantly differed. The data was analysed and graphed using GraphPad PRISM v.5 software (San Diego, CA, USA).

RESULTS
=======

*Parasitaemia levels of T. cruzi RyCH1 forms* - BALB/c mice that were inoculated i.p. with 1 x 104 trypomastigotes T. cruzi RyCH1 on days 0, 30 and 60 resulted in a development of the chronic phase of Chagas disease in Inf and Inf L-NAME groups. To comprehend the role of NO in the chronic phase of infection in vivo, L-NAME treatment was administrated by i.p injection (25 mg/Kg) once a week since day 0 (4 h p.i.) ([@B51], [@B19]) for the Inf L-NAME and Non-Inf L-NAME groups. Parasitaemia levels were determined in the infected groups (Inf and Inf L-NAME) by microscopic examination of tail vein blood every three days for two months. After two months, they were examined every 15 days, until day 195. The Inf group presented thin forms of the T. cruzi RyCH1 parasite on day 6 and then became undetectable after day 12. The thick forms of T. cruzi RyCH1 were detectable on day 6, with a peak of parasitaemia \[0.45 x 106 parasites blood forms/mL (PBF/mL)\] on day 27 ([Table I](#t01){ref-type="table"}). After day 42, the infection started to shift from the acute phase to the chronic phase, during which PBF became undetectable under microscopic examination ([Table I](#t01){ref-type="table"}). Interestingly, L-NAME promoted the earlier presence of thin forms of T. cruzi RyCH1 on day 3 and the thick forms on day 6, with a peak of parasitaemia on day 30, which was significantly higher than the Inf (0.54 x 106 PBF/mL, p \< 0.05) ([Table I](#t01){ref-type="table"}). In addition, with L-NAME treatment, blood parasitaemia were detectable until day 45 ([Table I](#t01){ref-type="table"}). Therefore, these data suggest L-NAME treatment, which causes a decrease in NO levels, is associated with an earlier detection of thin forms of T. cruzi RyCH1 and had a larger peak of parasitaemia at a later time.

TABLE IParasitaemia levels of Trypanosoma cruzi RyCH1 forms in infected non-treated (Inf) and infected N-monomethyl-L-arginine treated (Inf L-NAME) infected miceDayInfInf L-NAMEThin formsThick formsTotal/mLThin formsThick formsTotal/mL0\-\-\-\-\--3\-\--0.06 ± 0.24-0.06 ± 0.2461.45 ± 0.290.07 ± 0.011.53 ± 0.311.83 ± 0.220.08 ± 0.021.91 ± 0.2491.14 ± 0.251.40 ± 0.312.55 ± 0.561.34 ± 0.432.48 ± 0.673.82 ± 0.70120.95 ± 0.093.82 ± 0.394.78 ± 0.490.14 ± 0.084.96 ± 0.625.10 ± 0.6515-6.37 ± 0.576.37 ± 0.57-7.73 ± 0.727.73 ± 0.7218-9.45 ± 0.239.45 ± 0.23-6.70 ± 0.476.70 ± 0.4721-16.22 ± 1.4316.22 ± 1.43-15.20 ± 0.5115.20 ± 0.5124-29.16 ± 4.4329.16 ± 4.43-19.80 ± 0.9819.80 ± 0.9827-45.77 ± 3.9445.77 ± 3.94-36.93 ± 4.3036.93 ± 4.3030-19.16 ± 0.3119.16 ± 0.31-54.53 ± 3.1854.53 ± 3.1833-9.66 ± 0.609.66 ± 0.60-27.10 ± 1.6427.10 ± 1.6436-4.44 ± 0.374.44 ± 0.37-10.60 ± 0.9310.60 ± 0.9339-1.78 ± 0.161.78 ± 0.16-2.53 ± 0.442.53 ± 0.4442-0.16 ± 0.0470.16 ± 0.047-1.80 ± 0.0321.80 ± 0.03245\-\-\--0.53 ± 0.180.53 ± 0.1860-195\-\-\-\-\--[^1]

*Compartmental alteration and histopathological analysis of T. cruzi RyCH1* - Clinical manifestations of the chronic phase of Chagas disease \[slight alterations in fur colour (yellowish) with piloerection, especially in the dorsal region, hunched posture and decrease activity-level\] were observed at day 75 in Inf and Inf L-NAME mice and showed minimal physical differences when compare with previously reported mice models ([@B51], [@B19]). Non-Inf L-NAME and Non-Inf Veh mice presented with healthy physical and clinical characteristics (displayed with a white brilliant fur, showed no signs of peeling and were physically active) and did not manifest any side-effects related to the administration of either L-NAME or diluents controls, respectively. After day 135, Inf mice showed severe paralysis of the lower extremities when compared with Inf L-NAME mice (Supplementary data).


Histopathological analysis showed the presence of parasite nests in Inf mice starting at day 15 in skeletal muscle and heart tissues. As the time progressed, the maximum number of parasite nests was found to be in heart tissue followed by skeletal muscle on day 27 (p \< 0.01), with no significant presences in the diaphragm ([Table II](#t02){ref-type="table"}). This data correlates with the Inf group's peak of parasitaemia (day 27) ([Table I](#t01){ref-type="table"}). The Inf L-NAME group showed a similar tissue preference profile, with heart and muscle tissue having a significantly greater expression than other examined tissues (day 21, p \< 0.01). Interestingly, at the time for the peak of parasitaemia (day 30), the amount of nest is considerably fewer than day 21 ([Table II](#t02){ref-type="table"}). Furthermore, the L-NAME caused a reduced amount of nests in heart and muscle tissue (after day 27 and during the chronic phase) ([Table II](#t02){ref-type="table"}). In addition with the L-NAME treatment, we were able to detect nests in other tissues: colon, diaphragm and oesophagus (day 21) ([Table II](#t02){ref-type="table"}). Therefore, it seems that L-NAME allows the establishment of nests in multiple tissues, but counteracts the severity of the invasion.

TABLE IIPreferential tissue growth/survival of Trypanosoma cruzi RyCH1 in infected non-treated (Inf) and infected N-monomethyl-L-arginine treated (Inf L-NAME) groupsGroupInfDay p.i.15212733Muscle4.0 ± 2.519.5 ± 5.6a24.6 ± 8.0b7.0 ± 4.7Heart2.0 ± 0.818.5 ± 3.5a60.5 ± 20.2b11.2 ± 5.8Diaphragm\--1.4 ± 1.0-Colon\-\-\--Oesophagus\-\-\--GroupInf L-NAMEDay p.i.15212733Muscle17.5 ± 9.230.5 ± 15.1b14.8 ± 6.91.6 ± 0.6Heart4.0 ± 3.428.8 ± 11.2b11.8 ± 2.81.4 ± 1.2Diaphragm-2.0 ± 1.4\--Colon1.2 ± 0.81.0 ± 0.6\--Oesophagus-1.0 ± 0.7\--[^2]

To assess the severity of the invasion, we examined the heart and skeletal muscle tissue at day 135 p.i. The extensiveness of nest formation were examined by H&E staining of heart muscle ([Fig. 1 A, C](#f01){ref-type="fig"}) and skeletal muscle ([Fig. 1 B, D](#f01){ref-type="fig"}). We were able to view the presence of amastigote nests which were surrounded by lymphocytes infiltrate ([Fig. 1](#f01){ref-type="fig"}). Planes corresponding to the Inf group had an average of 7 ± 4 nest per a field, whereas the Inf L-NAME group had a significant lower amount (1.4 ± 1.2 nest per a field, p \< 0.01) for the heart ([Fig. 1 A, C](#f01){ref-type="fig"}). These results were similar for the skeletal muscle (3 ± 2.2 vs. 1.6 ± 0.57 for Inf and Inf L-NAME, respectively, p \< 0.01) ([Fig. 1 B, D](#f01){ref-type="fig"}). Therefore, these results suggest that L-NAME affects the development of nests during the chronic phase by an unknown mechanism.

Fig. 1: histopathological changes in heart and skeletal muscle of Trypanosoma cruzi RyCH1 in infected non-treated (Inf) and infected N-monomethyl-L-arginine treated (Inf L-NAME) groups. BALB/c mice were infected with 1 x 104 blood trypomastigotes of T. cruzi RyCH1. L-NAME was administered 25 μg/Kg intraperitoneally. Tissue samples were stained with haematoxylin and eosin and then examined by light microscope at 135 days post-infection. Lesions are representative of at least four animals in each group. Infiltrate inflammatory tissues are indicated by arrows. Bar indicates specific μm size. N: nest.

*NO levels of T. cruzi RyCH1 in Inf and the effected of L-NAME treatment* - We have demonstrated that NO levels are higher in patients with the chronic phase of Chagas disease ([@B40]). Therefore, the NO levels were determined in all of the groups using the Griess technique ([@B11]). The Inf group showed a progressive increase in NO levels, which reached a maximum value of 27.30 μmol/mL after day 165 ([Fig. 2 A](#f02){ref-type="fig"}). This was significantly higher than the non-infected mice (Non-Inf L-NAME and Non-Inf Veh, p \< 0.001). The Inf L-NAME group also showed an increase in NO levels, peaking at day 75, which was also significantly higher than the Inf group (15 μmol/mL vs. 12.5 μmol/mL, p \< 0.05). However, after day 75, the NO levels decreased and returned to basal levels (similar to Non-Inf L-NAME and Non-Inf Veh) by day 195 ([Fig. 2 A](#f02){ref-type="fig"}). This result was significantly lower than Inf (p \< 0.001). These data suggest that L-NAME, at 25 mg/Kg, did not block NO levels during the acute phase, allowing the development of the chronic phase of Chagas disease. Afterward, the NO levels decreased significantly, thereby preventing damage that is normally caused by NO during the chronic phase.

Fig. 2: time course of nitric oxide (NO) and metallothionein-1 (MT-I) levels in the liver of Trypanosoma cruzi RyCH1 in infected non-treated (Inf) and the effected of N-monomethyl-L-arginine (L-NAME) treatment. Inf and Inf L-NAME were intraperitoneally inoculated with 1 x 104 blood trypomastigotes of T. cruzi RyCH1 on day 0, 30 and 60. Inf L-NAME and non-infected L-NAME treated (Non-Inf L-NAME) received L-NAME once a week (25 mg/kg). Blood and liver RNA was collected from each group on day 3, 15 and 45, then every 30 days. A: NO levels determined by the Griess method; B: MT-I and G3PDH gene expression determined by semi-quantitative polymerase chain reaction. Results are mean ± standard error (n = 4). Data was normalised with expression levels of G3PDH. Non-Inf Veh: non-infected vehicle-treated.

*Liver levels of MT-I in T. cruzi RyCH1* - One protein of interest that can regulate NO levels is MT-I; therefore, the expression of MT-I was assessed in the murine model during the chronic phase. The mice were sacrificed at day 3, 15, 45 and then every 30 days. The liver RNA was collected and MT-I levels were determined using semi-qRT-PCR. The MT-I gene expression was significantly higher during the acute phase in the Inf group ([Fig. 2 B](#f02){ref-type="fig"}) (p \< 0.001); however, the MT-I levels decreased significantly as the time of infection prolonged (p \< 0.001). Whereas in the control groups (Non-Inf Veh and Non-Inf L-NAME), the MT-I expression levels presented no significant difference and remained constant. With the Inf L-NAME group, the MT-I expression significantly increased in a time-dependent manner with a maximum peak of expression at day 165. This peak was a 2.7-fold higher than the Inf group (p \< 0.001) ([Fig. 2 B](#f02){ref-type="fig"}). These data suggest that MT-I levels increased with the treatment of L-NAME during the chronic phase.

*Correlation of MT-I and NO during the chronic phase of Chagas disease* - MT production has been shown to increase in organisms exposed to high levels of reactive oxygen and nitrogen species ([@B31]). However, we observed an inverse correlation between the levels of MT-I and NO ([Fig. 3](#f03){ref-type="fig"}). While NO levels remained continuously high during the chronic phase ([Fig. 2 A](#f02){ref-type="fig"}, open circle), MT-I levels showed a decrease in expression ([Fig. 2](#f02){ref-type="fig"} B, open circle). Using these data, we determined an inverse correlation between NO levels and MT-I expression ( [Fig. 3 A](#f03){ref-type="fig"}) (r = -0.8462, p \< 0.0001). The same inverse correlation was evident when NO levels were inhibited by L-NAME ([Fig. 3 B](#f03){ref-type="fig"}) (r = -0.7480 p \< 0.001), which decreased the levels of NO ([Fig. 2 A](#f02){ref-type="fig"}, open boxes) and increased the levels of MT-I ([Fig. 2 B](#f02){ref-type="fig"}, open boxes). Therefore, during the chronic phase of Chagas disease, an inverse correlation between the levels of NO and MT-I was observed.

Fig. 3: Spearman's correlations between blood nitric oxide (NO) and liver metallothionein-1 (MT-I) levels during chronic phase of Chagas disease. BALB/c mice were inoculated with 1 x 104 blood trypomastigotes of Trypanosoma cruzi RyCH1 on day 0, 30 and 60 (Inf and Inf L-NAME). L-NAME was administered once weekly at 25 mg/kg \[infected non-treated (Inf) and infected N-monomethyl-L-arginine treated (Inf L-NAME)\]. Blood and liver RNA samples were collected on day 3, 15 and 45, then every 30 days. NO and MT-I level were determined by semi-quantitative reverse-transcriptase polymerase chain reaction. Sperman's correlation was determinate using Graph Pad PRISM v.5 software.

DISCUSSION
==========

Virulence, infectivity and pathogenesis of T. cruzi are mediated by the strain ([@B27], [@B8]). With Chagas disease, regional strain analysis is necessary for the development of targeted treatment options. The state of Puebla has an incidence rate of 7.7%, with the predominance in cardiac alterations ([@B44]). Our results have demonstrated that the HUM/ME/1997/MEX/RyCH1 (T. cruzi RyCH1) strain, using BALB/c mice as the host, was able to develop pathological and clinical characteristics of Chagas disease. This allowed us to analyse the chronic phase of the disease as observed in the population of Puebla. In our murine model, the physical changes corresponding to the chronic phase appeared after day 45, which correlated with absence of circulating parasites. These physical characteristics are consistent with other murine models, featuring alterations in fur colour with piloerection, hunched posture and severe paralysis of the lower extremities ([@B5]). Kinetics of parasitaemia in this model also showed similar levels to other well-studied strains in chronic phase ([Table I](#t01){ref-type="table"}), such as T. cruzi Tulahuén, 21SF, Mambai, Bolivia, TBAR/MX/0000/Queretaro and MHOM/MX/1994/Ninoa ([@B1], [@B42], [@B8]). Therefore, we are led to conclude that our model is physically similar to other murine models of Chagas disease. In addition, parasitaemia levels for both groups were undetectable, as seen previously with other T. cruzi strains during the chronic phase ([@B8], [@B13]). Moreover, the preferential tissue growth study demonstrated that during the acute phase, L-NAME did significantly alter the severity of the infection, allowed infection to progress in organs in which parasitism is usually low/undetectable ([Table II](#t02){ref-type="table"}). The levels of parasitism in these organs, when compared to other strains, were unique for this strain ([@B12]).

Normally, NO is required by the immune system to eradicate the parasite during the acute phase of the infection. If NO levels decrease, then augmented parasitaemia will eventually lead to the death of the murine host ([@B51], [@B19]). Treatment with NO inhibitors resulted in an increase in parasitaemia and mortality during the acute phase ([@B42], [@B18], [@B17], [@B32]). However, it is still not clear what effect elevated blood NO levels has on patients with the chronic phase of Chagas disease. L-NAME, a NO inhibitor, was administrated once a week between day 0 (4 h p.i.) to the end of experiment, at a dose of 25 mg/Kg/week. This diverges from other published treatments and doses. Other groups ordinarily treated with \~5 mg/Kg per/day, which corresponds to between 25-35 mg/kg each week ([@B42], [@B18], [@B32]). This dose of 25 mg/kg/week allowed mice to survive the acute phase of infection and develop the chronic phase of Chagas disease without decreasing their survival rate. In contrast, most mice treated with 5 mg/Kg/day developed a severe acute phase, which eventually led to a high parasite burden and death ([@B42], [@B18], [@B32]).

When the mice were treated with L-NAME at 25 mg/kg/week (Inf L-NAME), two notable effects on NO levels were observed. NO levels increased during the acute phase with no significant variation until day 75 (p \< 0.05) ([Fig. 3](#f03){ref-type="fig"}). Our purposed explanation is that the administration of L-NAME at 4 h p.i affected the NO production during the first few days of the infection. This allowed the parasite to propagate quickly in blood, as demonstrated by the presence of the thin/immature forms of T. cruzi at an earlier timeframe ([Table I](#t01){ref-type="table"}). The reason for the earlier detection of the thin/immature forms we are currently examining. We speculate that the increases of the thick/mature forms in blood are due to a block in tissue tropism. We were able to see a decrease of nest in L-NAME treated mice after day 27 ([Table II](#t02){ref-type="table"}) and day 135 ([Fig. 1 C, D](#f01){ref-type="fig"}). The second notable affect was, at the initiation of the chronic phase (\> day 75), NO levels decreased significantly in Inf L-NAME mice due to the L-NAME treatment (p \< 0.001). This correlated with the undetectable parasitaemia levels and the lower nest present in tissues. In addition, it also correlated with the significantly higher levels of MT-I.

Many researchers have demonstrated that the trypomastigotes of T. cruzi are cleared by the liver ([@B49], [@B34], [@B45]). During inflammation, toxin insults and oxidative stress damage caused increased expression of MTs in the liver ([@B46], [@B36]). Although published results suggest that an elevation in NO levels will lead to an elevation in MT-I levels as a protective mechanism ([@B2], [@B15], [@B21], [@B24], [@B3]), our results demonstrate the contrary. When we evaluated the MT-I levels during the chronic phase of Chagas disease, the Inf group demonstrated a reduced MT-I level when the NO level was elevated ([Fig. 2 A](#f02){ref-type="fig"}). However, with the L-NAME treated mice, when the NO level was low, the MT-I level was high ([Fig. 2 B](#f02){ref-type="fig"}). A correlation analysis determined that this was a strong inverse relationship ([Fig. 3](#f03){ref-type="fig"}). The mechanism for this inverse relationship is currently unknown. We suggest that the chronic inflammation caused by Chagas disease, which is signified by high levels of NO, may led to a down regulation of MT-I. This is in agreement with the clinical data ([@B37], [@B38]). Inflammatory cytokines tumour necrosis factor-alpha and interleukin-6 have been shown to regulate MTs family proteins ([@B25], [@B22], [@B23]). Therefore, during the chronic phase of Chagas disease, we suggest that MT-I could be down-regulated by these pro-inflammatory cytokines. It will be crucial to further investigate and characterise the mechanism involved in the inhibition of MT-I during the chronic phase of Chagas disease.
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[^1]: BALB/c mice were inoculated with 1 x 104 blood trypomastigotes of HUM/ME/1997/MEX/RyCH1 or T. cruzi RyCH1 on days 0, 30 and 60 in the Inf and Inf L-NAME groups. Treatment with L-NAME was administered with a 25 μg/Kg intraperitoneal injection once a week for Inf L-NAME, beginning on day 0 (4 h post-infection). Parasitaemia peaks are shown in bold. The values represent parasite blood forms x 104/mL.

[^2]: a: p \< 0.05; b: p \< 0.001. BALB/c mice were inoculated with 1 x 104 blood trypomastigotes of HUM/ME/1997/MEX/RyCH1 or T. cruzi RyCH1 on days 0, 30 and 60 in the Inf and Inf L-NAME groups. Treatment with L-NAME was administered with a 25 μg/Kg intraperitoneal injection once a week for L-NAME, beginning on day 0. Number of parasite nests in tissue sample was determinate with haematoxylin and eosin staining at the indicated day. p.i.: post-infection.
